These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10474138)

  • 1. A unified theory for sequential clinical trials.
    Whitehead J
    Stat Med; 1999 Sep 15-30; 18(17-18):2271-86. PubMed ID: 10474138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress.
    Biswas A
    Stat Methods Med Res; 2001 Oct; 10(5):353-64. PubMed ID: 11697227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical principles: myths or facts?
    Sylvester R
    Onkologie; 2003 Dec; 26(6):520-1. PubMed ID: 14709923
    [No Abstract]   [Full Text] [Related]  

  • 7. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive sequential testing for multiple comparisons.
    Gao P; Liu L; Mehta C
    J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unified method for monitoring and analysing controlled trials.
    Grossman J; Parmar MK; Spiegelhalter DJ; Freedman LS
    Stat Med; 1994 Sep; 13(18):1815-26. PubMed ID: 7997715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case against independent monitoring committees.
    Harrington D; Crowley J; George SL; Pajak T; Redmond C; Wieand S
    Stat Med; 1994 Jul 15-30; 13(13-14):1411-4. PubMed ID: 7973220
    [No Abstract]   [Full Text] [Related]  

  • 13. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis: the alpha spending function approach.
    DeMets DL; Lan KK
    Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group sequential designs using a family of type I error probability spending functions.
    Hwang IK; Shih WJ; De Cani JS
    Stat Med; 1990 Dec; 9(12):1439-45. PubMed ID: 2281231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliably basing conclusions on subgroups of randomized clinical trials.
    Koch A; Framke T
    J Biopharm Stat; 2014; 24(1):42-57. PubMed ID: 24392977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
    Wu J; Xiong X
    J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.